Literature DB >> 12130689

Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor.

Bryan Goodwin1, Ecushla Hodgson, Daniel J D'Costa, Graham R Robertson, Christopher Liddle.   

Abstract

Cytochrome P450 3A4 (CYP3A4), the predominant P450 expressed in adult human liver, is both constitutively expressed and transcriptionally activated by a variety of structurally diverse xenochemicals. In this study, we examined the role of the constitutive androstane receptor (CAR), a member of the steroid/retinoid/thyroid hormone receptor superfamily, in the transcriptional regulation of CYP3A4. Herein, we demonstrate that CAR is capable of trans-activating expression of the CYP3A4 gene, both in vitro and in vivo. Induction of CYP3A4 is dependent on cooperativity between elements within the promoter proximal region of the gene and the distal xenobiotic-responsive enhancer module. CAR responsiveness was shown to be primarily mediated by two high-affinity binding motifs located within the CYP3A4 gene 5'-flanking region, approximately 7720 and 150 bases upstream of the transcription initiation site. Importantly, the human CAR response elements also mediate trans-activation of CYP3A4 by the human pregnane X receptor, suggesting that interplay between these receptors is likely to be an important determinant of CYP3A4 expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130689     DOI: 10.1124/mol.62.2.359

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  59 in total

Review 1.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

2.  CYP3A phenotypes and genotypes in North Indians.

Authors:  Naushad Rais; Yogesh K Chawla; Krishan K Kohli
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

Review 3.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.

Authors:  E J Reschly; Matthew D Krasowski
Journal:  Curr Drug Metab       Date:  2006-05       Impact factor: 3.731

Review 4.  Transcriptional Regulation of CYP2D6 Expression.

Authors:  Xian Pan; Miaoran Ning; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2016-10-03       Impact factor: 3.922

Review 5.  Small-molecule modulators of the constitutive androstane receptor.

Authors:  Milu T Cherian; Sergio C Chai; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-05-15       Impact factor: 4.481

6.  Phenytoin induction of the cyp2c37 gene is mediated by the constitutive androstane receptor.

Authors:  Jonathan P Jackson; Stephen S Ferguson; Masahiko Negishi; Joyce A Goldstein
Journal:  Drug Metab Dispos       Date:  2006-08-25       Impact factor: 3.922

7.  Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.

Authors:  Li-Qun Yang; Shen-Jing Li; Yun-Fei Cao; Xiao-Bo Man; Wei-Feng Yu; Hong-Yang Wang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

8.  Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.

Authors:  M A Perera; R K Thirumaran; N J Cox; S Hanauer; S Das; C Brimer-Cline; V Lamba; E G Schuetz; M J Ratain; A Di Rienzo
Journal:  Pharmacogenomics J       Date:  2008-09-30       Impact factor: 3.550

9.  Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR).

Authors:  J P Hernandez; L C Mota; W Huang; D D Moore; W S Baldwin
Journal:  Toxicology       Date:  2008-11-11       Impact factor: 4.221

10.  Phenobarbital elicits unique, early changes in the expression of hepatic genes that affect critical pathways in tumor-prone B6C3F1 mice.

Authors:  Jennifer M Phillips; Lyle D Burgoon; Jay I Goodman
Journal:  Toxicol Sci       Date:  2009-03-06       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.